Market for advanced heart valve care to reach US$12.91b by 2034: report

This comes as interest in minimally invasive surgical processes grows.

The global transcatheter aortic valve replacement (TAVR) market size is expected to reach US$12.91b by 2034, according to Polaris Market Research.

TAVR, also known as transcatheter aortic valve implantation, is a less invasive process of replacing a damaged or failing aortic valve with an artificial valve, Polaris said in its TAVR analysis for North America, Europe, Asia, Latin America, and the Middle East.  

The valve replacement market size stands at US$7.22b in 2025, it added.

It expects the sector to gain 6.7% Compound Annual Growth Rate (CAGR) between 2025 and 2035.

The TAVR market will grow amidst growing interest in minimally invasive surgical procedures and advancements in TAVR devices.

Imaging methods such as CT scans and 3D echocardiography are helping accurate planning and execution of TAVR, Polaris said.

Key players in the sector include Abbott Laboratories, Boston Scientific Corporation, HLT, Inc., Medtronic plc, and St. Jude Medical Inc., amongst others, it added.

Based on end use, the hospitals segment led the market with an 89.4% revenue share of the sector’s global market in 2024.

The segment’s growth was driven by the prevalence of aortic stenosis, an increase in TAVR treatments, and favourable reimbursement policies in both developed and developing countries.

North America led the global market with a 40% revenue share in 2024, spurred by an advanced healthcare system and rising rates of disorders such as aortic stenosis and aortic regurgitation in the region.

Polaris said that TAVR has several advantages over open-heart surgery, including lower discomfort, less blood loss, and reduced infection risks. 

Patients undergoing TAVR can usually walk the same day as their procedure and go home the next day, it added.